Transfusion therapy evidence-based recommendations for the pediatric cancer patient

Pardo-González, Carlos Alberto; Linares, Adriana; Torres, Marcela

doi:10.1016/j.rcae.2016.02.006

Cited by 3 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This depends on the degree of myelosuppression and condition of the cell lines, as well as the complications and comorbidities present, such as hemorrhages, surgical pathologies, and sepsis. Therefore, we also assessed the indications for transfusion, highlighting anemia and thrombocytopenia in more than 90% of the patients, agreeing with what was expressed by Pardo et al [8] and Flores [20], who also indicated that oncological pathology alone suppresses hematopoiesis, triggering anemia and thrombocytopenia. Additionally, it was determined that the RBCs were transfused at an average volume close to 10 ml/kg, mostly at 121-180 minutes; however, there are no studies based on these variables, but the transfusions carried out were carried out following established protocols, such as those detailed by the Spanish Society of Blood Transfusion and Cellular Therapies [2].…”

Section: Transfusionssupporting

confidence: 86%

“…The incidence of ATRs in adults is lower than in pediatric patients, with an average of 252 and 538-620/100,000 transfusions, respectively [7]. In medical practice, it has been shown that hemato-oncology patients are exposed to continuous transfusions due to the myelosuppression they suffer from their underlying disease or because of myeloablative and immunosuppressive treatment, reflecting spinal depression with low hemoglobin, platelet, and absolute neutrophil counts [8,9].…”

Section: Introductionmentioning

confidence: 99%

“…At the Latin American level, in 2017, 57% of the patients were diagnosed with concentrated red blood cells (RBCs), 21.6% with platelet concentrates (PCs), 14% with fresh frozen plasma (FFP), 3% with cryoprecipitates and 3.5% with platelets obtained by apheresis [10]. In the European survey, 15,367 oncological patients were evaluated; at six months, the prevalence of anemia was 39%, and the incidence was 53.7%, with 14.9% requiring transfusion [8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Características transfusionales y hemovigilancia de los pacientes pediátricos con cáncer

Urdiales Valarezo,

Guerrero Quiroz

2023

REV-SEP

View full text Add to dashboard Cite

Introducción: La terapia transfusional no está libre de riesgos, siendo los pacientes hemato- oncológicos los mayores transfundidos, por ello la necesidad de la hemovigilancia. El objetivo del presente estudio fue identificar las características transfusionales y la hemovigilancia de los pacientes pediátricos con cáncer en el Instituto SOLCA-Cuenca, enero-diciembre 2021. Método: Se realizó un estudio descriptivo con todos los pacientes menores de 18 años que requirieron transfusiones y todas las hemotransfusiones realizadas en SOLCA-Cuenca 2021. Los datos fueron recolectados en un formulario previamente validado y se analizaron en el programa SPSS v25.0, presentándose como frecuencias, porcentajes, media y desviación estándar. Resultados: Se estudiaron 73 pacientes y 620 transfusiones, predominando: adolescentes (45.2 %), de sexo masculino (63 %), mestizos (98.6 %), urbanos (76.7%), grupo ORH+ (83.5 %). Con leucemia linfoblástica aguda células B (49.3 %) y quimioterapia de inducción (41.1 %). El 58.9 % tenían antecedente transfusional y 4.1 % reacción previa (urticaria). La media transfusional por paciente fue 8,49 y, 7,1% fueron premedicadas con esteroides; se transfundieron principalmente concentrados eritrocitarios (49%) por anemia (95.4 %) a 9,32ml/kg (media) en 121 a 180 minutos (56.9 %). Del 3.1 % de reacciones evidenciadas, el 100% fueron inmediatas, no infecciosas (urticaria 84.2 %), definitivas y se trataron con medicamentos (84.2 % esteroide); el 79 % de reacciones fueron leves; fueron secundarias a concentrados eritrocitarios (47.4 %), aféresis (47.4 %) y; evidenciadas en pacientes con leucemia linfoblástica aguda células B (31.5 %). Conclusiones: Los pacientes con leucemia linfoblástica aguda células B requirieron más transfusiones sanguíneas, principalmente concentrados eritrocitarios; mientras las reacciones transfusionales se asociaron frecuentemente a concentrados eritrocitarios y aféresis.

show abstract

Section: Transfusionssupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Características transfusionales y hemovigilancia de los pacientes pediátricos con cáncer

Urdiales Valarezo,

Guerrero Quiroz

2023

REV-SEP

View full text Add to dashboard Cite

show abstract

“…Some advocate for therapeutic-only treatment or when there is an increased risk of bleeding due to co-morbidity ( 70 ). Others recommend prophylactic cryoprecipitate in all oncology patients with acquired hypofibrinogenemia secondary to medications ( 72 , 73 ).…”

Section: Indications For Fibrinogen Replacement In the Critical Care Settingmentioning

confidence: 99%

Pediatric Fibrinogen PART II—Overview of Indications for Fibrinogen Use in Critically Ill Children

Crighton

Huisman

2021

Front. Pediatr.

View full text Add to dashboard Cite

Bleeding is frequently seen in critically ill children and is associated with increased morbidity and mortality. Fibrinogen is an essential coagulation factor for hemostasis and hypofibrinogenemia is an important risk factor for bleeding in pediatric and adult settings. Cryoprecipitate and fibrinogen concentrate are often given to critically ill children to prevent bleeding and improve fibrinogen levels, especially in the setting of surgery, trauma, leukemia, disseminated intravascular coagulopathy, and liver failure. The theoretical benefit of fibrinogen supplementation to treat hypofibrinogenemia appears obvious, yet the evidence to support fibrinogen supplementation in children is sparce and clinical indications are poorly defined. In addition, it is unknown what the optimal fibrinogen replacement product is in children and neonates or what the targets of treatment should be. As a result, there is considerable variability in practice. In this article we will review the current pediatric and applicable adult literature with regard to the use of fibrinogen replacement in different pediatric critical care contexts. We will discuss the clinical indications for fibrinogen supplementation in critically ill children and the evidence to support their use. We summarize by highlighting current knowledge gaps and areas for future research.

show abstract

“…Occasionally, blood transfusion may be administered. Although this could be seen as controversial in the dying patient, justification is based on whether transfusion has the potential to improve the patient's symptoms [27]. Catastrophic bleeding, as may be seen in acute pulmonary haemorrhage, can be both a distressing and terminal event.…”

Section: Bleedingmentioning

confidence: 99%

Palliative Care of the Infant and Child in the Paediatric Intensive Care Unit

McAllister¹,

Crowe²,

Charra³

et al. 2021

Suggestions for Addressing Clinical and Non-Clinical Issues in Palliative Care

View full text Add to dashboard Cite

In this chapter we discuss the delivery of palliative care in the paediatric intensive care unit environment. Illustrated by challenging cases, we describe the role of intensive care in symptom management for the child with terminal or life-limiting illness. We detail the importance of a multidisciplinary team and their roles in the provision of individualised care for the child and their family. The importance of family-centred care and advance care planning is expanded upon. In addition, we explore end of life issues that are particular to children in intensive care such as withdrawal of life-sustaining therapies and organ donation. Finally, we discuss how to ensure the delivery of high-quality palliative care in the paediatric intensive care environment.

show abstract

Transfusion therapy evidence-based recommendations for the pediatric cancer patient

Cited by 3 publications

References 16 publications

Características transfusionales y hemovigilancia de los pacientes pediátricos con cáncer

Características transfusionales y hemovigilancia de los pacientes pediátricos con cáncer

Pediatric Fibrinogen PART II—Overview of Indications for Fibrinogen Use in Critically Ill Children

Palliative Care of the Infant and Child in the Paediatric Intensive Care Unit

Contact Info

Product

Resources

About